Expanding the genotypic and phenotypic landscapes of rhizomelic chondrodysplasia punctata type 3 (RCDP3) with two novel families, and a review of the literature

Rhizomelic chondrodysplasia punctata (RCDP) are a group of peroxisomal disorders caused by plasmalogen synthesis defects. Patients with RCDP present with rhizomelic short stature, characteristic punctate epiphyseal calcifications, congenital cataracts, severe intellectual disability, seizures, and facial dysmorphism. Pathogenic variants in AGPS result in RCDP type 3 (RCDP3) which is an extremely rare disorder characterized by isolated ADHAPS deficiency. Six patients with RCDP3 have been identified, upto‐date. We report two new patients with RCDP3 and their novel variants, c.154dupG (p.Ala52GlyfsTer6) and c.637+1G>A, in the AGPS gene. We also present a review of previously reported RCDP3 patients.

[1]  H. Waterham,et al.  Clinical, biochemical, and molecular characterization of mild (nonclassic) rhizomelic chondrodysplasia punctata , 2020, Journal of inherited metabolic disease.

[2]  B. Poll-The,et al.  Rhizomelic chondrodysplasia punctata morbidity and mortality, an update , 2019, American journal of medical genetics. Part A.

[3]  N. Braverman,et al.  Oral administration of a synthetic vinyl-ether plasmalogen normalizes open field activity in a mouse model of rhizomelic chondrodysplasia punctata , 2019, Disease Models & Mechanisms.

[4]  S. Ferdinandusse,et al.  Human disorders of peroxisome metabolism and biogenesis. , 2016, Biochimica et biophysica acta.

[5]  N. Braverman,et al.  Congenital heart defects common in rhizomelic chondrodysplasia punctata , 2016, American journal of medical genetics. Part A.

[6]  D. Misceo,et al.  A novel type of rhizomelic chondrodysplasia punctata, RCDP5, is caused by loss of the PEX5 long isoform. , 2015, Human molecular genetics.

[7]  N. Blom,et al.  Rhizomelic Chondrodysplasia Punctata and cardiac pathology , 2013, Journal of Medical Genetics.

[8]  A. Moser,et al.  Rhizomelic Chondrodysplasia Punctata Type 1 , 2012 .

[9]  A. Moser,et al.  Functional characterization of novel mutations in GNPAT and AGPS, causing rhizomelic chondrodysplasia punctata (RCDP) types 2 and 3 , 2012, Human mutation.

[10]  M. Irving,et al.  Chondrodysplasia punctata: a clinical diagnostic and radiological review , 2008, Clinical dysmorphology.

[11]  M. Durán,et al.  MRI of the brain and cervical spinal cord in rhizomelic chondrodysplasia punctata , 2006, Neurology.

[12]  R. Wanders,et al.  Human alkyldihydroxyacetonephosphate synthase deficiency: A new peroxisomal disorder , 1994, Journal of Inherited Metabolic Disease.

[13]  R. Pauli,et al.  Natural history of rhizomelic chondrodysplasia punctata , 2003, American journal of medical genetics. Part A.

[14]  A. Moser,et al.  Impaired membrane traffic in defective ether lipid biosynthesis. , 2001, Human molecular genetics.

[15]  H. Moser,et al.  Ether lipid biosynthesis: alkyl-dihydroxyacetonephosphate synthase protein deficiency leads to reduced dihydroxyacetonephosphate acyltransferase activities. , 1999, Journal of lipid research.

[16]  R. Wanders,et al.  Alkyl-dihydroxyacetone phosphate synthase and dihydroxyacetone phosphate acyltransferase form a protein complex in peroxisomes. , 1999, European journal of biochemistry.

[17]  R. Wanders,et al.  Alkyl-Dihydroxyacetonephosphate Synthase , 1998, The Journal of Biological Chemistry.

[18]  H. Moser,et al.  Human PEX7 encodes the peroxisomal PTS2 receptor and is responsible for rhizomelic chondrodysplasia punctata , 1997, Nature Genetics.